casirivimab+imdevimab
R10933-10987-COV-2114
Phase 2 small_molecule terminated
Quick answer
casirivimab+imdevimab for COVID-19 is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- COVID-19
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated